Independent directory Public ClinicalTrials.gov records United States
ClinicalTrials.gov record
Completed Phase 3 Interventional Results available

Double-blind, Randomized Study Evaluating the Efficacy and Safety of Brivaracetam in Adults With Partial Onset Seizures

ClinicalTrials.gov ID: NCT00464269

Public ClinicalTrials.gov record NCT00464269. Field values are reproduced from the official study page; the official ClinicalTrials.gov record remains the source of truth for eligibility, enrollment, and contact information.

ClinicalTrials.gov public records Last synced Jul 22, 2026, 5:09 PM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Official title

An International, Double-blind, Parallel-group, Placebo-controlled, Randomized Study: Evaluation of the Efficacy and Safety of Brivaracetam in Subjects (>= 16 to 70 Years Old) With Partial Onset Seizures

Study identification

NCT ID
NCT00464269
Recruitment status
Completed
Study type
Interventional
Phase
Phase 3
Lead sponsor
UCB Pharma
Industry
Enrollment
400 participants

Conditions and interventions

Conditions

Interventions

  • Placebo Other
  • Brivaracetam 2.5 mg Drug
  • Brivaracetam 10 mg Drug
  • Brivaracetam 25 mg Drug

Other · Drug

Eligibility (public fields only)

Age range
16 Years to 70 Years
Sex
All
Healthy volunteers
Healthy volunteers not accepted

This page does not interpret eligibility. Detailed inclusion and exclusion criteria are on the official ClinicalTrials.gov record.

Study timeline

Start date
Aug 31, 2007
Primary completion
Nov 30, 2008
Completion
Dec 31, 2008
Last update posted
Jul 20, 2022

2007 – 2009

United States locations

U.S. sites
40
U.S. states
25
U.S. cities
40
Facility City State ZIP Site status
Not listed Phoenix Arizona
Not listed Tucson Arizona
Not listed Little Rock Arkansas
Not listed Fresno California
Not listed Los Angeles California
Not listed Newport Beach California
Not listed Sacramento California
Not listed San Francisco California
Not listed Washington D.C. District of Columbia
Not listed Atlanta Georgia
Not listed Augusta Georgia
Not listed Chicago Illinois
Not listed Springfield Illinois
Not listed Wichita Kansas
Not listed Lexington Kentucky
Not listed Louisville Kentucky
Not listed Baltimore Maryland
Not listed Bethesda Maryland
Not listed Burlington Massachusetts
Not listed Detroit Michigan
Not listed Grand Rapids Michigan
Not listed Saint Paul Minnesota
Not listed Tupelo Mississippi
Not listed Chesterfield Missouri
Not listed St Louis Missouri
Not listed New York New York
Not listed Rochester New York
Not listed Cincinnati Ohio
Not listed Columbus Ohio
Not listed Portland Oregon
Not listed Philadelphia Pennsylvania
Not listed Greenville South Carolina
Not listed Nashville Tennessee
Not listed Dallas Texas
Not listed Houston Texas
Not listed Salt Lake City Utah
Not listed Charlottesville Virginia
Not listed Richmond Virginia
Not listed Seattle Washington
Not listed Milwaukee Wisconsin

Site contact phone numbers, emails, and investigator names are intentionally not displayed here. Open the official ClinicalTrials.gov record for site contact information.

Non-U.S. locations

This page focuses on the U.S. directory. The official record also lists 29 non-U.S. sites.

About this trial record page

What this page shows
Public field values for ClinicalTrials.gov record NCT00464269, including study identification, conditions, interventions, eligibility (age, sex, healthy volunteer), timeline, and U.S. site list.
What this page does not do
No medical advice, eligibility judgments, treatment recommendations, study quality scoring, or AI-generated medical summaries. No site contact phone numbers, emails, or investigator names.
Where the data comes from
Sourced from the official ClinicalTrials.gov public API. The official record is the source of truth.
Last refresh
Last update posted Jul 20, 2022 · Synced Jul 22, 2026

Related: full search, browse by condition, browse by drug or therapy, browse by sponsor, browse by U.S. city.

Open the official record

The complete protocol, eligibility criteria, and contact information for NCT00464269 live on ClinicalTrials.gov.

View official ClinicalTrials.gov record →